Details for Patent: 9,408,840

Which drugs does patent 9,408,840 protect, and when does it expire?

Patent 9,408,840 protects IBSRELA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-one countries.

Summary for Patent: 9,408,840

Title:	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder
Abstract:	The present disclosure is directed to compounds of the structure (X): CoreL-NHE).sub.n (X) wherein: n is 2 or 3; NHE has the structure ##STR00001## wherein: R.sup.1 is H or --SO.sub.2--NR.sub.7R.sub.8--; R.sup.2 is selected from H, --NR.sub.7(CO)R.sub.8, --SO.sub.2--NR.sub.7R.sub.8-- and --NR.sub.7R.sub.8; R.sup.3 is hydrogen; R.sup.7 is hydrogen; R.sup.8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: ##STR00002## wherein: X is selected from the group consisting of a bond, --O--, --NH--, NHC(.dbd.O)--, --NHC(.dbd.O)NH-- and --NHSO.sub.2--; and Y is selected from the group consisting of a bond, optionally substituted C.sub.1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and --(CH.sub.2).sub.1-6O(CH.sub.2).sub.1-6--, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.
Inventor(s):	Bell; Noah (Fremont, CA), Carreras; Christopher (Fremont, CA), Charmot; Dominique (Fremont, CA), Jacobs; Jeffrey W. (Fremont, CA), Leadbetter; Michael Robert (Fremont, CA), Navre; Marc (Fremont, CA)
Assignee:	Ardelyx, Inc. (Fremont, CA)
Application Number:	14/592,200
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,408,840

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes						METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR

International Family Members for US Patent 9,408,840

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009334511
Brazil	PI0923861
Canada	2748607